Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

India approves Eli Lilly’s Mounjaro KwikPen, a once-weekly injection for type 2 diabetes and obesity, offering dual hormone action for improved blood sugar control and significant weight loss.

Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017.

Eli Lilly blamed the misses on drug wholesalers cutting inventory of Zepbound and Mounjaro.